# A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

> **NCT02814175** · PHASE4 · COMPLETED · sponsor: **AbbVie** · enrollment: 246 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** methotrexate (MTX)
- **BIOLOGICAL:** adalimumab (ADA)

## Key facts

- **NCT ID:** NCT02814175
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-05
- **Primary completion:** 2019-09-23
- **Final completion:** 2020-03-19
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02814175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02814175, "A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02814175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*